IPSEF News and Press, Ipsen Sa Ord From 06/02/21

Ipsen (IPSEY) to buyback 500K shares, or about 0.6% of the share capital, over a maximum period of six months.The shares purchased under this agreement will be allocated mainly to cover its free performance share-allocation plans and its new employee share-ownership plan. For further detail...

Ipsen (IPSEY) has launched an Employee Shareholding plan. This transaction will be carried out through the sale of existing shares reserved for members of the company and will be capped to a number of shares representing a maximum of 1% of the company's share capital. The subscription price i...

Fusion Pharmaceuticals (FUSN) has completed the acquisition of IPN-1087, a small molecule targeting tumors, from Ipsen (IPSEY).Fusion intends to use IPN-1087, which targets the protein neurotensin receptor 1 (NTSR1), to create an alpha-emitting radiopharmaceutical, FPI-2059, for sol...

Ipsen S.A. (IPSEY) Q4 2020 Earnings Conference Call February 11, 2021, 08:30 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - EVP and Group CFO Conference Call Participants Matthew Weston - Credit Suisse Michael Leuchten - UBS Emily Field - Barclays Sarita Kapila - JPMorgan ...

Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (EXEL) disclosed new data for Opdivo/ Cabometyx combo in a pivotal Phase 3 trial for the first-line treatment of advanced renal cell carcinoma.The trial sponsored by Bristol Myers Squibb and Ono Pharmaceutical (OPHLF) and co-funded by Exelix...

Bristol Myers Squibb (BMY) and Exelixis (EXEL) announce results from the pivotal Phase 3 CheckMate -9ER trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma ((RCC)).A total of 651 patients were randomized to Opdivo (nivolumab) plus CABOMETYX (ca...

Ipsen S.A. ( OTCPK:IPSEF ) : 1H Non-GAAP EPS of €3.55; GAAP EPS of €2.65. More news on: Ipsen S.A., Ipsen S.A., Earnings news and commentary, Healthcare stocks news, Read more ...

Ipsen ( OTCPK:IPSEF ) has appointed David Loew as its new Chief Executive Officer and as Board member, effective on July 1, 2020. More news on: Ipsen S.A., Read more ...

Quick Take Lantern Pharma ( LTRN ) intends to raise $25 million in gross proceeds from an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of drug treatment candidates identified by its proprietary RADR platform. LTRN believes it can b...

Quick Take Lantern Pharma ( LTRN ) has filed to raise $28.75 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing a pipeline of drug candidates for the treatment of prostate, lung and other cancers. LTRN seeks to use its proprietary ...